ATAI
tid tid placebo screening randomizing week efficacy function safety and tolerability compliance week end of trial week exit phone call safety and tolerability compliance primary at week adaptive design interim analyses for futility of one or both doses success sample size estimation phase randomized week study in patients with | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
36 of 41
Related slides by other companies
MindMed
Investor Presentation
November 2024
phase trial schematic schematic | MindMed
MindMed
Investor Presentation
December 2024
for phase study design design | MindMed
MindMed
Investor Presentation
November 2024
phase trial schematic emerge study study week gee toe a study single dose of for | MindMed
AstraZeneca
Investor Day
February 2022
fact quality of life over time | AstraZeneca
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io